Infliximab for the treatment of acute exacerbations of ulcerative colitis.

Health technology assessment (Winchester, England)

Volumn 14 Suppl 1, Issue , 2010, Pages 9-15

  Bryan, S ^a   Andronis, L ^b   Hyde, C ^b   Connock, M ^b   Fry Smith, A ^b   Wang, D ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY;

ACUTE DISEASE; COLON RESECTION; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; MORTALITY; QUALITY OF LIFE; REVIEW; RISK; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; CYCLOSPORINE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, ECONOMIC; QUALITY OF LIFE; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84886943186     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta14suppl1/02     Document Type: Review

References (0)